Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis
The trial is a randomized, double-blind, placebo-controlled study of approximately 400 patients across 50 sites.
In addition, the Company announced the enrollment of the first patient in a clinical trial to evaluate the safety and efficacy of XHANCE for treatment of adolescent pediatric patients with nasal polyps.
The pediatric trial is a randomized, double-blind, placebo-controlled study of approximately 120 patients across 30 sites.
"We are particularly pleased to be initiating our clinical program in pursuit of an indication for treatment of Chronic Sinusitis because we are aware of no approved drugs for that indication, and we believe there is a very large population in need of treatment,” said Dr.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the anticipated commencement of the second chronic sinusitis trial in 2019; the potential to achieve the first ever drug approval for chronic sinusitis; and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: uncertainties and delays relating to the initiation, enrollment, completion and results of clinical trials; risks relating to regulatory approval of XHANCE for chronic sinusitis; market opportunities for XHANCE may be smaller than the Company believes; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the Company’s most recent Form 10-K and Form 10-Q filings with the
Optinose Investor Contact